Physician profile
William K Stone
NPI 1548240856
$10,416.35
in general payments reported to CMS, 2019-2025
33 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,593 · 2020: $915 · 2021: $1,492 · 2022: $1,668 · 2023: $1,589 · 2024: $1,421 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,704 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,703.65 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,726.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,348.48 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $808.96 | 2019-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $754.79 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $728.76 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $690.94 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $608.85 | 2019-2022 | |
| Pfizer INC. | $495.98 | 2019-2025 | |
| Abbvie INC. | $457.86 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Merck Sharp & Dohme LLC | $252.73 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $172.33 | 2023-2025 | Rexulti |
| Abbott Laboratories | $164.00 | 2022-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $155.88 | 2019-2022 | |
| Glaxosmithkline, LLC. | $153.67 | 2019-2025 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $122.78 | 2024-2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $87.76 | 2020-2025 | Austedo Xr |
| Daiichi Sankyo INC. | $82.30 | 2019-2022 | |
| Eisai INC. | $75.66 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $75.33 | 2019-2024 | |
| Exact Sciences Corporation | $64.47 | 2023-2025 | Cologuard Collection Kit |
| Teleflex LLC | $60.89 | 2025 | Urolift |
| Dexcom, INC. | $45.23 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $44.62 | 2022 | |
| Esperion Therapeutics, INC. | $41.62 | 2025 | Nexletol |
| Amarin Pharma, INC. | $35.68 | 2019 | |
| Idorsia Pharmaceuticals US INC | $28.97 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $28.54 | 2025 | Gemtesa |
| Shire North American Group INC | $21.93 | 2019 | |
| Medtronic, INC. | $21.28 | 2025 | Interstim |
| Alexion Pharmaceuticals, INC. | $17.86 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.52 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $13.40 | 2022 | |
| Axsome Therapeutics, INC. | $12.06 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.